GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Cdkn1a | decreases methylation | EXP | | 6480464 | CTD | Decitabine results in decreased methylation of CDKN1A promoter | PMID:30649504 | Cdkn1a | affects expression | ISO | CDKN1A (Homo sapiens) | 6480464 | CTD | [Decitabine affects the expression of DNMT3B protein] which affects the expression of CDKN1A mRNA; Decitabine affects the expression of CDKN1A mRNA | PMID:18544619 PMID:23300844 | Cdkn1a | decreases methylation | ISO | CDKN1A (Homo sapiens) | 6480464 | CTD | Decitabine results in decreased methylation of CDKN1A gene; Decitabine results in decreased methylation of CDKN1A promoter | PMID:19234609 PMID:27543423 PMID:30649504 | Cdkn1a | increases expression | ISO | Cdkn1a (Mus musculus) | 6480464 | CTD | Decitabine results in increased expression of CDKN1A mRNA | PMID:25549359 PMID:27915011 | Cdkn1a | increases expression | ISO | CDKN1A (Homo sapiens) | 6480464 | CTD | Decitabine results in increased expression of CDKN1A; Decitabine results in increased expression of CDKN1A mRNA; Decitabine results in increased expression of CDKN1A protein | PMID:12859993 PMID:14722112 PMID:15753979 PMID:16043219 PMID:17417771 PMID:17977830 PMID:18025290 PMID:18223691 PMID:18845559 PMID:19234609 PMID:19422044 PMID:21801466 PMID:22534328 PMID:22749965 | Cdkn1a | multiple interactions | ISO | Cdkn1a (Mus musculus) | 6480464 | CTD | [Decitabine co-treated with Valproic Acid] results in increased expression of CDKN1A mRNA | PMID:19155313 | Cdkn1a | multiple interactions | ISO | CDKN1A (Homo sapiens) | 6480464 | CTD | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Decitabine results in increased expression of CDKN1A protein]; [4-phenylbutyric acid co-treated with Decitabine] results in increased expression of CDKN1A mRNA; [Decitabine co-treated with trichostatin A] affects the expression of CDKN1A mRNA; [Decitabine co-treated with trichostatin A] results in increased expression of CDKN1A protein; [Decitabine promotes the reaction [TP53 protein binds to CDKN1A promoter]] which results in increased expression of CDKN1A protein; [Decitabine results in increased expression of and affects the localization of CDKN1A protein] which results in increased activity of TP53 protein; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with Decitabine] results in increased expression of CDKN1A mRNA; AZD 6244 promotes the reaction [Decitabine results in increased expression of CDKN1A]; belinostat promotes the reaction [Decitabine results in increased expression of CDKN1A mRNA]; belinostat promotes the reaction [Decitabine results in increased expression of CDKN1A protein]; Caffeine inhibits the reaction [Decitabine results in increased expression of CDKN1A protein]; Decitabine inhibits the reaction [HDAC1 protein binds to CDKN1A promoter]; Decitabine inhibits the reaction [Sodium Fluoride results in decreased expression of CDKN1A mRNA]; Decitabine inhibits the reaction [Sodium Fluoride results in decreased expression of CDKN1A protein]; Decitabine inhibits the reaction [Sodium Fluoride results in increased methylation of CDKN1A promoter]; Decitabine promotes the reaction [Resveratrol results in increased expression of CDKN1A mRNA]; Decitabine promotes the reaction [TP53 protein modified form binds to CDKN1A promoter]; Decitabine results in increased expression of and affects the localization of CDKN1A protein; entinostat promotes the reaction [Decitabine results in increased expression of CDKN1A protein]; Phenylbutyrates promotes the reaction [Decitabine results in increased expression of CDKN1A protein]; pifithrin inhibits the reaction [Decitabine results in increased expression of CDKN1A protein]; TP53 affects the reaction [Decitabine results in increased expression of CDKN1A protein]; TP53 gene mutant form inhibits the reaction [Decitabine results in increased expression of CDKN1A protein]; TP53 protein affects the reaction [Decitabine results in increased expression of CDKN1A protein]; TP53 protein modified form affects the reaction [Decitabine results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [Decitabine results in increased expression of CDKN1A protein]; trichostatin A promotes the reaction [Decitabine results in increased expression of CDKN1A mRNA]; trichostatin A promotes the reaction [Decitabine results in increased expression of CDKN1A protein]; Valproic Acid promotes the reaction [Decitabine results in increased expression of CDKN1A protein] | PMID:14722112 PMID:15753979 PMID:16043219 PMID:17185465 PMID:17210717 PMID:17389721 PMID:17977830 PMID:18223691 PMID:19234609 PMID:19422044 PMID:21801466 PMID:22534328 PMID:31669217 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |